1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
Saved in:
| Title: | 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC) |
|---|---|
| Authors: | Vansteenkiste, J.F.1 (AUTHOR), Demedts, I.2 (AUTHOR), Pons-Tostivint, E.3 (AUTHOR), Biesma, B.4 (AUTHOR), Borm, F.5 (AUTHOR), Colinet, B.6 (AUTHOR), Cuppens, K.7 (AUTHOR), Derijcke, S.8 (AUTHOR), Greillier, L.9 (AUTHOR), Jürgens, J.10 (AUTHOR), Moro-Sibilot, D.11 (AUTHOR), Pérol, M.12 (AUTHOR), Sebastian, M.13 (AUTHOR), Skrzypski, M.14 (AUTHOR), Theelen, W.15 (AUTHOR), Van De Kerkhove, C.16 (AUTHOR), Collodoro, M.17 (AUTHOR), Plumas, J.18 (AUTHOR), Debruyne, C.19 (AUTHOR), Sibille, A.20 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1086-S1086. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.1299 |
